Περίληψη:
Hepatitis C virus (HCV) infection is a major public health problem in the European Union (EU). An estimated 5.6 million Europeans are chronically infected with a wide range of variation in prevalence across European Union countries. Although HCV continues to spread as a largely “silent pandemic,” its elimination is made possible through the availability of the new antiviral drugs and the implementation of prevention practices. On 17 February 2016, the Hepatitis B & C Public Policy Association held the first EU HCV Policy Summit in Brussels. This summit was an historic event as it was the first high-level conference focusing on the elimination of HCV at the European Union level. The meeting brought together the main stakeholders in the field of HCV: clinicians, patient advocacy groups, representatives of key institutions and regional bodies from across European Union; it served as a platform for one of the most significant disease elimination campaigns in Europe and culminated in the presentation of the HCV Elimination Manifesto, calling for the elimination of HCV in Europe by 2030. The launch of the Elimination Manifesto provides a starting point for action in order to make HCV and its elimination in Europe an explicit public health priority, to ensure that patients, civil society groups and other relevant stakeholders will be directly involved in developing and implementing HCV elimination strategies, to pay particular attention to the links between hepatitis C and social marginalization and to introduce a European Hepatitis Awareness Week. © 2018 John Wiley & Sons Ltd
Συγγραφείς:
Papatheodoridis, G.V.
Hatzakis, A.
Cholongitas, E.
Baptista-Leite, R.
Baskozos, I.
Chhatwal, J.
Colombo, M.
Cortez-Pinto, H.
Craxi, A.
Goldberg, D.
Gore, C.
Kautz, A.
Lazarus, J.V.
Mendão, L.
Peck-Radosavljevic, M.
Razavi, H.
Schatz, E.
Tözün, N.
van Damme, P.
Wedemeyer, H.
Yazdanpanah, Y.
Zuure, F.
Manns, M.P.
Λέξεις-κλειδιά:
antivirus agent; antivirus agent, antiviral therapy; cost benefit analysis; epidemic; Europe; European Union; France; Germany; global disease burden; hepatitis C; high risk population; human; infection prevention; Italy; Netherlands; patient advocacy; Portugal; priority journal; program sustainability; public health; public policy; quality of life; Review; Scotland; social exclusion; viral clearance; disease eradication; economics; epidemiological monitoring; Hepacivirus; hepatitis C; organization and management; physiology; prevalence; virology, Antiviral Agents; Disease Eradication; Epidemiological Monitoring; Europe; European Union; Hepacivirus; Hepatitis C; Humans; Prevalence
